Griendling KK, Touyz RM, Zweier JL, Dikalov S, Chilian W, Chen YR, Harrison DG, Bhatnagar A, American Heart Association Council on Basic Cardiovascular Sciences
[5] Despite presenting its product as an alternative to other medications that work to treat obesity, the advertisement obscures the fact that Hims weight loss medications are unapproved, compounded products that have not been subject to clinical testing or FDA scrutiny and pose a higher risk to patients than FDA-approved drugs. [6] Most alarmingly, the commercial makes no mention of side-effects, warnings, or the potentially serious risks posed by any semaglutide product
After reconstitution in a sterile aqueous vehicle for laboratory use, BPC-157 solutions should be held at 4C and used within 48 hours
12 The REWIND trial evaluated dulaglutide in a broader population, including those with a lower baseline cardiovascular risk, and demonstrated a significant reduction in composite cardiovascular outcomes, together with a favourable trend in HF-related events